Regeneron Announces Agreement With BARDA Supporting Development Of Next-Generation Antibody Therapy For COVID-19 Prevention
Portfolio Pulse from Happy Mohamed
Regeneron Pharmaceuticals has announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of a next-generation COVID-19 monoclonal antibody therapy. The agreement is part of 'Project NextGen,' an initiative by the U.S. Department of Health and Human Services to advance new vaccines and therapeutics for COVID-19. The new contract has an estimated value of up to approximately $326 million of government funding.
August 22, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's agreement with BARDA for the development of a next-generation COVID-19 antibody therapy could potentially bring significant government funding and boost the company's research and development efforts.
The agreement with BARDA not only provides financial support for Regeneron's research and development efforts but also strengthens the company's position in the market as a leading developer of COVID-19 therapeutics. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100